ACE and chronic kidney disease: Across all patient cohorts, the cost-effectiveness of screening for CKD was most sensitive to changes in SGLT2 inhibitor effectiveness and costs of ACE inhibitors/ARBs and SGLT2 inhibitors (Figure 3; eFigures 1-5 in Supplement 1).